ArticleLeukemia2016
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- EANM guidelines on the use of [European journal of nuclear medicine and molecular imaging · 2024Guideline
- Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [European journal of nuclear medicine and molecular imaging · 2026Trial
- Application of an artificial intelligence-based tool in [European journal of nuclear medicine and molecular imaging · 2023Trial
- Diagnosis, risk stratification and management of smouldering multiple myeloma.Nature reviews. Clinical oncology · 2026Review
- Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.Blood advances · 2025Review
- Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis.Clinical lymphoma, myeloma & leukemia · 2025Article
- Body Composition Metrics Associated with Time to Progression in Smoldering Multiple Myeloma.Diagnostics (Basel, Switzerland) · 2025Article
- Simultaneous whole-body multi-parametric 2-[Leukemia · 2025Article
- Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions.Diagnostics (Basel, Switzerland) · 2025Review
- Detection of myeloma-associated osteolytic bone lesions with energy-integrating and photon-counting detector CT.Radiologie (Heidelberg, Germany) · 2024Article
- Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.Hematology/oncology clinics of North America · 2024Review
- Detecting bone marrow infiltration in nonosteolytic multiple myeloma through separation of hydroxyapatite via the two-material decomposition technique in spectral computed tomography.Quantitative imaging in medicine and surgery · 2024Article
- Hybrid simultaneous whole-body 2-[European radiology · 2023Article
- New Developments in Myeloma Treatment and Response Assessment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.Biomedicines · 2023Review
- Modern imaging techniques for monitoring patients with multiple myeloma.Medicine and pharmacy reports · 2022Review
- Smoldering multiple myeloma current treatment algorithms.Blood cancer journal · 2022Review
- Modern radiographic imaging in multiple myeloma, what is the minimum requirement?Seminars in oncology · 2022Review
- Role of FDG PET in the staging of multiple myeloma.Skeletal radiology · 2022Review
- Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.Frontiers in oncology · 2022Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrated with computed tomography (PET/CT) using glucose labelled with the positron-emitting radionuclide (18)F) allows for assessing early skeletal involvement. Identification of osteolytic lesions by this technique has recently been incorporated into the updated International Myeloma Working Group criteria for MM diagnosis. However, no data are available regarding the impact of focal lesions (FLs) without underlying osteolysis on time to progression (TTP) to MM. We hence prospectively studied a cohort of 120 SMM patients with PET/CT. PET/CT was positive in 16% of patients (1 FL: 8, 2 FLs: 3, >3 FLs: 6, diffuse bone marrow involvement: 2). With a median follow-up of 2.2 years, 38% of patients progressed to MM, in a median time of 4 years, including 21% with skeletal involvement. The risk of progression of those with positive PET/CT was 3.00 (95% confidence interval 1.58-5.69, P=0.001), with a median TTP of 1.1 versus 4.5 years for PET/CT-negative patients. The probability of progression within 2 years was 58% for positive versus 33% for negative patients. In conclusion, PET/CT positivity significantly increased the risk of progression of SMM to MM. PET/CT could become a new tool to define high-risk SMM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.